Sawyers C. Targeted cancer therapy. Nature. 2004;432:294–7.

Article  CAS  PubMed  Google Scholar 

Hahn VS, Zhang KW, Sun L, Narayan V, Lenihan DJ, Ky B. Heart failure with targeted cancer therapies: mechanisms and cardioprotection. Circ Res. 2021;128:1576–93.

Article  CAS  PubMed  Google Scholar 

Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. Npj Precis Oncol. 2018;2:13.

Article  PubMed  Google Scholar 

Rocca C, De Francesco EM, Pasqua T, Granieri MC, De Bartolo A, Gallo Cantafio ME, et al. Mitochondrial determinants of anti-cancer drug-induced cardiotoxicity. Biomedicines. 2022;10:520.

Article  CAS  PubMed  Google Scholar 

Rocca C, Soda T, De Francesco EM, Fiorillo M, Moccia F, Viglietto G, et al. Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer. J Transl Med. 2023;21:635.

Article  PubMed  Google Scholar 

Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther. 2019;4:34.

Article  PubMed  Google Scholar 

Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–87.

Article  CAS  PubMed  Google Scholar 

Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25:2033–41.

Article  CAS  PubMed  Google Scholar 

Romond EH, Jeong J-H, Rastogi P, Swain SM, Geyer CE, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by Paclitaxel (ACP) With ACP Plus Trastuzumab as adjuvant therapy for patients with node-positive, human epidermal Gr. J Clin Oncol. 2012;30:3792–9.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

Article  CAS  PubMed  Google Scholar 

Hussain Y, Drill E, Dang CT, Liu JE, Steingart RM, Yu AF. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. Breast Cancer Res Treat. 2019;175:239–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525–33.

Article  CAS  PubMed  Google Scholar 

Rocca C, Pasqua T, Cerra MC, Angelone T. Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation. Antioxid Redox Signal. 2020;32:1081–97.

Article  CAS  PubMed  Google Scholar 

Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459–65.

Article  CAS  PubMed  Google Scholar 

Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443–6.

Article  CAS  PubMed  Google Scholar 

Méndez-Valdés G, Gómez-Hevia F, Bragato MC, Lillo-Moya J, Rojas-Solé C, Saso L, et al. Antioxidant protection against Trastuzumab cardiotoxicity in breast cancer therapy. Antioxidants. 2023;12:457.

Article  PubMed  PubMed Central  Google Scholar 

Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, et al. Role of Fcγ receptors in HER2-targeted breast cancer therapy. J Immunother Cancer. 2022;10:e003171.

Article  PubMed  PubMed Central  Google Scholar 

Wang D, Wei X, Wang Z, Lu Y, Shi S, Wang N, et al. FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer. Onco Targets Ther. 2017;10:5065–76.

Article  PubMed  PubMed Central  Google Scholar 

Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G Fragment C receptor polymorphisms and clinical efficacy of Trastuzumab-based therapy in patients with HER-2/neu–positive metastatic breast cancer. J Clin Oncol. 2008;26:1789–96.

Article  CAS  PubMed  Google Scholar 

Staudt A, Eichler P, Trimpert C, Felix SB, Greinacher A. FcγReceptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol. 2007;49:1684–92.

Article  CAS  PubMed  Google Scholar 

Patel P, Michael JV, Naik UP, McKenzie SE. Platelet FcγRIIA in immunity and thrombosis: adaptive immunothrombosis. J Thromb Haemost. 2021;19:1149–60.

Article  PubMed  Google Scholar 

Kholodenko RV, Kalinovsky DV, Doronin II, Ponomarev ED, Kholodenko IV. Antibody fragments as potential biopharmaceuticals for cancer therapy: success and limitations. Curr Med Chem. 2019;26:396–426.

Article  CAS  PubMed  Google Scholar 

Selis F, Sandomenico A, Cantile M, Sanna R, Calvanese L, Falcigno L, et al. Generation and testing of engineered multimeric Fabs of trastuzumab. Int J Biol Macromol. 2020;164:4516–31.

Article  CAS  PubMed  Google Scholar 

Davidson M, Nesti C, Palenzuela L, Walker W, Hernandez E, Protas L, et al. Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol. 2005;39:133–47.

Article  CAS  PubMed  Google Scholar 

Liang JL, Xiao DZ, Liu XY, Lin QX, Shan ZX, Zhu JN, et al. High glucose induces apoptosis in AC16 human cardiomyocytes via macrophage migration inhibitory factor and c-Jun N-terminal kinase. Clin Exp Pharmacol Physiol. 2010;37:969–73.

Article  CAS  PubMed  Google Scholar 

De Bartolo A, Pasqua T, Romeo N, Rago V, Perrotta I, Giordano F, et al. The redox-active defensive Selenoprotein T as a novel stress sensor protein playing a key role in the pathophysiology of heart failure. J Transl Med. 2024;22:375.

Article  PubMed  PubMed Central  Google Scholar 

Zheng Y, Lakshmanan S. Dose-dependent efficacy of umbelliferone and gelatin-coated ZnO/ZnS core-shell nanoparticles: a novel arthritis agent for severe knee arthritis. Oxid Med Cell Longev. 2022;2022:1–15.

Google Scholar 

Grande F, De Bartolo A, Occhiuzzi MA, Caruso A, Rocca C, Pasqua T, et al. Carbazole and simplified derivatives: novel tools toward β-adrenergic receptors targeting. Appl Sci. 2021;11:5486.

Article  CAS  Google Scholar 

Rocca C, De Bartolo A, Grande F, Rizzuti B, Pasqua T, Giordano F, et al. Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction. Int Immunopharmacol. 2021;94:107487.

Article  CAS  PubMed  Google Scholar 

McQueen MJ. Optimal assay of LDH and α-HBD at 37 °C. Ann Clin Biochem Int J Lab Med. 1972;9:21–5.

Article  CAS  Google Scholar 

Rocca C, De Bartolo A, Guzzi R, Crocco MC, Rago V, Romeo N, et al. Palmitate-induced cardiac lipotoxicity is relieved by the redox-active motif of SELENOT through improving mitochondrial function and regulating metabolic state. Cells. 2023;12:1042.

Article  CAS  PubMed  Google Scholar 

Rocca C, Scavello F, Colombo B, Gasparri AM, Dallatomasina A, Granieri MC, et al. Physiological levels of chromogranin A prevent doxorubicin‐induced cardiotoxicity without impairing its anticancer activity. FASEB J. 2019;33:7734–47.

Article  CAS